...
search icon
tcrx-img

Tscan Therapeutics Inc Share Price

TCRX
NMQ
$1.02
+$0.04
(4.1%)
1D
Industry: Biotechnology Sector: Health Care

Tscan Therapeutics Inc Analyst Forecast

Tscan Therapeutics Inc Share Price Chart

Tscan Therapeutics Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$55.35M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.60M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.04
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.88 L
$2.57 H
$1.02

About Tscan Therapeutics Inc, Common Stock

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. more

Industry: BiotechnologySector: Health Care

Tscan Therapeutics Inc Stock Returns

Time FrameTCRXSectorS&P500
1-Week Return10.04%0.72%-1.31%
1-Month Return-4.46%1.27%0.78%
3-Month Return8.07%3.13%3.46%
6-Month Return-40.22%15.81%6.19%
1-Year Return-46.77%8.89%11.68%
3-Year Return-61.23%20.79%71.21%
5-Year Return-89.81%35.89%74.81%

Tscan Therapeutics Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue1.08M10.14M13.54M21.05M2.82M[{"date":"2020-12-31","value":5.15,"profit":true},{"date":"2021-12-31","value":48.18,"profit":true},{"date":"2022-12-31","value":64.3,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":13.38,"profit":true}]
Cost of Revenue20.58M3.33M5.14M88.15M4.11M[{"date":"2020-12-31","value":23.34,"profit":true},{"date":"2021-12-31","value":3.78,"profit":true},{"date":"2022-12-31","value":5.83,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":4.66,"profit":true}]
Gross Profit(19.49M)10.14M13.54M21.05M2.82M[{"date":"2020-12-31","value":-92.6,"profit":false},{"date":"2021-12-31","value":48.18,"profit":true},{"date":"2022-12-31","value":64.3,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":13.38,"profit":true}]
Gross Margin(1796.50%)100.00%100.00%100.00%100.00%[{"date":"2020-12-31","value":-1796.5,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses6.74M58.78M80.17M114.51M137.64M[{"date":"2020-12-31","value":4.9,"profit":true},{"date":"2021-12-31","value":42.71,"profit":true},{"date":"2022-12-31","value":58.25,"profit":true},{"date":"2023-12-31","value":83.19,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(26.23M)(48.64M)(66.64M)(93.46M)(134.82M)[{"date":"2020-12-31","value":-2623300000,"profit":false},{"date":"2021-12-31","value":-4864100000,"profit":false},{"date":"2022-12-31","value":-6663600000,"profit":false},{"date":"2023-12-31","value":-9345800000,"profit":false},{"date":"2024-12-31","value":-13482100000,"profit":false}]
Total Non-Operating Income/Expense212.00K32.00K830.00K6.66M15.73M[{"date":"2020-12-31","value":1.35,"profit":true},{"date":"2021-12-31","value":0.2,"profit":true},{"date":"2022-12-31","value":5.28,"profit":true},{"date":"2023-12-31","value":42.34,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(26.13M)(48.63M)(66.22M)(89.22M)(127.50M)[{"date":"2020-12-31","value":-2612700000,"profit":false},{"date":"2021-12-31","value":-4862500000,"profit":false},{"date":"2022-12-31","value":-6622100000,"profit":false},{"date":"2023-12-31","value":-8921800000,"profit":false},{"date":"2024-12-31","value":-12749900000,"profit":false}]
Income Taxes(106.00K)3.09M(415.00K)5.19M-[{"date":"2020-12-31","value":-2.04,"profit":false},{"date":"2021-12-31","value":59.53,"profit":true},{"date":"2022-12-31","value":-7.99,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(26.02M)(51.72M)(65.81M)(94.41M)-[{"date":"2020-12-31","value":-2602100000,"profit":false},{"date":"2021-12-31","value":-5171644200,"profit":false},{"date":"2022-12-31","value":-6580600000,"profit":false},{"date":"2023-12-31","value":-9441110500,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(26.13M)(48.64M)(66.22M)(88.33M)(127.50M)[{"date":"2020-12-31","value":-2612700000,"profit":false},{"date":"2021-12-31","value":-4864100000,"profit":false},{"date":"2022-12-31","value":-6622100000,"profit":false},{"date":"2023-12-31","value":-8832800000,"profit":false},{"date":"2024-12-31","value":-12749900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(26.13M)(48.63M)(66.22M)(89.22M)(127.50M)[{"date":"2020-12-31","value":-2612700000,"profit":false},{"date":"2021-12-31","value":-4862500000,"profit":false},{"date":"2022-12-31","value":-6622100000,"profit":false},{"date":"2023-12-31","value":-8921800000,"profit":false},{"date":"2024-12-31","value":-12749900000,"profit":false}]
EPS (Diluted)-(9.98)(2.75)(1.89)(1.15)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-998,"profit":false},{"date":"2022-12-31","value":-275,"profit":false},{"date":"2023-12-31","value":-189,"profit":false},{"date":"2024-12-31","value":-115,"profit":false}]

Tscan Therapeutics Inc Ratios

Tscan Therapeutics Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

TCRX
Cash Ratio 6.32
Current Ratio 6.44

Tscan Therapeutics Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

TCRX
ROA (LTM) -30.45%
ROE (LTM) -76.44%

Tscan Therapeutics Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

TCRX
Debt Ratio Lower is generally better. Negative is bad. 0.45
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.55

Tscan Therapeutics Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

TCRX
Trailing PE NM
Forward PE NM
P/S (TTM) 6.57
P/B 0.37
Price/FCF NM
EV/R 0.34
EV/Ebitda 0.39

FAQs

What is Tscan Therapeutics Inc share price today?

Tscan Therapeutics Inc (TCRX) share price today is $1.02

Can Indians buy Tscan Therapeutics Inc shares?

Yes, Indians can buy shares of Tscan Therapeutics Inc (TCRX) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TCRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Tscan Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Tscan Therapeutics Inc (TCRX) via the Vested app. You can start investing in Tscan Therapeutics Inc (TCRX) with a minimum investment of $1.

How to invest in Tscan Therapeutics Inc shares from India?

You can invest in shares of Tscan Therapeutics Inc (TCRX) via Vested in three simple steps:

  • Click on Sign Up or Invest in TCRX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Tscan Therapeutics Inc shares
What is Tscan Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Tscan Therapeutics Inc (TCRX) is $2.57. The 52-week low price of Tscan Therapeutics Inc (TCRX) is $0.88.

What is Tscan Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Tscan Therapeutics Inc (TCRX) is

What is Tscan Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Tscan Therapeutics Inc (TCRX) is 0.37

What is Tscan Therapeutics Inc dividend yield?

The dividend yield of Tscan Therapeutics Inc (TCRX) is 0.00%

What is the Market Cap of Tscan Therapeutics Inc?

The market capitalization of Tscan Therapeutics Inc (TCRX) is $55.35M

What is Tscan Therapeutics Inc's stock symbol?

The stock symbol (or ticker) of Tscan Therapeutics Inc is TCRX

How Can Investors Use Tscan Therapeutics Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Tscan Therapeutics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Tscan Therapeutics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Tscan Therapeutics Inc shares for Indian investors?

When investing in Tscan Therapeutics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Tscan Therapeutics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Tscan Therapeutics Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Tscan Therapeutics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Tscan Therapeutics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top